Future Screening Prospects for Ovarian Cancer
Current diagnostic tools used in clinical practice such as transvaginal ultrasound, CA 125, and HE4 are not sensitive and specific enough to diagnose OC in the early stages. A lack of early symptoms and an effective asymptomatic population screening strategy leads to a poor prognosis in OC. New diag...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/15/3840 |
id |
doaj-ec45e0467fc14d449a36a18fff63ccc4 |
---|---|
record_format |
Article |
spelling |
doaj-ec45e0467fc14d449a36a18fff63ccc42021-08-06T15:20:40ZengMDPI AGCancers2072-66942021-07-01133840384010.3390/cancers13153840Future Screening Prospects for Ovarian CancerDiana Žilovič0Rūta Čiurlienė1Rasa Sabaliauskaitė2Sonata Jarmalaitė3Life Sciences Center, Institute of Biosciences, Vilnius University, Saulėtekio Avenue 7, LT-10222 Vilnius, LithuaniaOncogynecology Department, National Cancer Institute, Santariškių 1, LT-08406 Vilnius, LithuaniaLaboratory of Genetic Diagnostic, National Cancer Institute, Santariškių 1, LT-08406 Vilnius, LithuaniaLaboratory of Clinical Oncology, National Cancer Institute, Santariškių 1, LT-08406 Vilnius, LithuaniaCurrent diagnostic tools used in clinical practice such as transvaginal ultrasound, CA 125, and HE4 are not sensitive and specific enough to diagnose OC in the early stages. A lack of early symptoms and an effective asymptomatic population screening strategy leads to a poor prognosis in OC. New diagnostic and screening methods are urgently needed for early OC diagnosis. Liquid biopsies have been considered as a new noninvasive and promising method, using plasma/serum, uterine lavage, and urine samples for early cancer detection. We analyzed recent studies on molecular biomarkers with specific emphasis on liquid biopsy methods and diagnostic efficacy for OC through the detection of circulating tumor cells, circulating cell-free DNA, small noncoding RNAs, and tumor-educated platelets.https://www.mdpi.com/2072-6694/13/15/3840ovarian cancerliquid biopsiesuterine lavagehigh-throughput methodsNGS-based multigene panels |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Diana Žilovič Rūta Čiurlienė Rasa Sabaliauskaitė Sonata Jarmalaitė |
spellingShingle |
Diana Žilovič Rūta Čiurlienė Rasa Sabaliauskaitė Sonata Jarmalaitė Future Screening Prospects for Ovarian Cancer Cancers ovarian cancer liquid biopsies uterine lavage high-throughput methods NGS-based multigene panels |
author_facet |
Diana Žilovič Rūta Čiurlienė Rasa Sabaliauskaitė Sonata Jarmalaitė |
author_sort |
Diana Žilovič |
title |
Future Screening Prospects for Ovarian Cancer |
title_short |
Future Screening Prospects for Ovarian Cancer |
title_full |
Future Screening Prospects for Ovarian Cancer |
title_fullStr |
Future Screening Prospects for Ovarian Cancer |
title_full_unstemmed |
Future Screening Prospects for Ovarian Cancer |
title_sort |
future screening prospects for ovarian cancer |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-07-01 |
description |
Current diagnostic tools used in clinical practice such as transvaginal ultrasound, CA 125, and HE4 are not sensitive and specific enough to diagnose OC in the early stages. A lack of early symptoms and an effective asymptomatic population screening strategy leads to a poor prognosis in OC. New diagnostic and screening methods are urgently needed for early OC diagnosis. Liquid biopsies have been considered as a new noninvasive and promising method, using plasma/serum, uterine lavage, and urine samples for early cancer detection. We analyzed recent studies on molecular biomarkers with specific emphasis on liquid biopsy methods and diagnostic efficacy for OC through the detection of circulating tumor cells, circulating cell-free DNA, small noncoding RNAs, and tumor-educated platelets. |
topic |
ovarian cancer liquid biopsies uterine lavage high-throughput methods NGS-based multigene panels |
url |
https://www.mdpi.com/2072-6694/13/15/3840 |
work_keys_str_mv |
AT dianazilovic futurescreeningprospectsforovariancancer AT rutaciurliene futurescreeningprospectsforovariancancer AT rasasabaliauskaite futurescreeningprospectsforovariancancer AT sonatajarmalaite futurescreeningprospectsforovariancancer |
_version_ |
1721218867130269696 |